Beclometasone/formoterol

Beclometasone/formoterol

Combination of
Beclometasone dipropionate	Glucocorticoid
Formoterol fumarate	Long-acting β2 agonist
Clinical data
Trade names	Fostair, Luforbec, Bibefco, Proxor, Vivaire [1]
AHFS/Drugs.com	International Drug Names
Routes of administration	Inhalation
ATC code	R03AL09 ( WHO )
Legal status
Legal status	AU: S4 (Prescription only) [2] UK: POM (Prescription only) [3] [4] [5]

Beclometasone/formoterol, sold under the brand name Fostair, Proxor, Vivaire and Luforbec, is an inhalable fixed-dose combination drug for the treatment of asthma and chronic obstructive pulmonary disease (COPD). ^[3] It contains beclometasone dipropionate and formoterol fumarate dihydrate. It is inhaled. ^[3]

It was approved for medical use in the United Kingdom in 2007, ^[3] and in Australia in February 2020. ^{[6] [7]} It is on the World Health Organization's List of Essential Medicines. ^[8]

References

1. "Beclometasone with formoterol". BNF. Retrieved 21 May 2025.
2. "Becloform (Cipla Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 16 April 2025. Retrieved 3 May 2025.
3. "Fostair 100/6 micrograms per actuation pressurised inhalation solution - Summary of Product Characteristics (SmPC)". (emc). 3 March 2020. Retrieved 18 July 2020.
4. "Fostair 200/6 micrograms per actuation pressurised inhalation solution - Summary of Product Characteristics (SmPC)". (emc). 13 February 2019. Retrieved 18 July 2020.
5. "Fostair NEXThaler 200 micrograms/6 micrograms per actuation inhalation powder - Summary of Product Characteristics (SmPC)". (emc). 16 April 2019. Retrieved 18 July 2020.
6. "Australian Product Information - Fostair 100/6 (Beclometasone dipropionate and formoterol (eformoterol) fumarate dihydrate) pressurised inhalation solution". Therapeutic Goods Administration (TGA). April 2020. Retrieved 22 September 2020.
7. "AusPAR: Beclometasone dipropionate/formoterol (eformoterol) fumarate dihydrate". Therapeutic Goods Administration (TGA). 3 August 2020. Retrieved 22 September 2020.
8. World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533 . WHO/MHP/HPS/EML/2021.02.

Further reading

• Foster K, Wong CY (July 2024). "Advances in inhaler therapy for asthma and chronic obstructive pulmonary disease: a comprehensive review of Fostair and Trimbow". Journal of Pharmacy and Pharmacology. doi:10.1093/jpp/rgae090. PMID   38954755.